Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area

NCT03008122 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

91

Enrollment

NIH

Sponsor class

Conditions

Zika Virus Infection

Interventions

OTHER: Placebo
BIOLOGICAL: Zika Virus Purified Inactivated Vaccine (ZPIV)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)